Section 7.1 Laboratory
Laboratory Report #21
Date
Collection Date: June 7, 2022
Report Date: June 17, 2022
Laboratory
Labcorp
Performing Laboratory: Monogram Biosciences Inc.
Ordering Physician
Dr. D. Yoo
Medical City Heart / Spine
Report Type
Pharmacogenomic Evaluation
Laboratory testing included:
- Cytochrome P450 2C19 (CYP2C19) Genotyping
Clinical indication:
- Paroxysmal Atrial Fibrillation
Original Report
PDF: Labcorp – June 7, 2022
One-Page Summary
Purpose of Testing
This laboratory evaluation was performed as part of cardiovascular management to determine how the body metabolizes medications processed through the CYP2C19 enzyme pathway. CYP2C19 genetic testing is used to help physicians understand whether a patient is a normal, intermediate, poor, or rapid metabolizer of certain medications, particularly drugs such as clopidogrel (Plavix) that require CYP2C19 activation.
This testing was ordered in the context of paroxysmal atrial fibrillation and cardiovascular care under Dr. Yoo.
Major Finding
CYP2C19 Genotype
Result
- **CYP2C19 Genotype: 1/2
CYP2C19 Metabolic Activity
Result
- Intermediate Metabolizer
Interpretation
The CYP2C19 gene affects the activity of an important liver enzyme involved in processing several medications.
Your genetic result:
*One normal-function allele (1)
+
*One reduced-function allele (2)
results in:
Intermediate CYP2C19 metabolism
This means the enzyme has reduced activity compared with a normal metabolizer, but activity is not completely absent.
Clinical Significance
Medication Implications
Individuals with an intermediate CYP2C19 metabolism pattern may process certain medications differently.
The most clinically recognized example is:
Clopidogrel (Plavix)
Clopidogrel is a “prodrug,” meaning it requires activation by CYP2C19.
Individuals with reduced CYP2C19 activity may:
- Convert clopidogrel to its active form less efficiently.
- Potentially have reduced antiplatelet effect.
- Require consideration of alternative medications or strategies depending on clinical circumstances.
Relevance to Health Inventory
This report is particularly relevant to:
Cardiovascular History
- Paroxysmal atrial fibrillation
- Watchman device history
- Anticoagulation/antiplatelet decisions
- Cardiologist management
Medication Management
This genetic information may help physicians consider:
- Medication selection
- Medication effectiveness
- Potential drug interactions
The result should always be interpreted together with:
- Age
- Kidney function
- Liver function
- Other medications
- Medical history
- Clinical response
Overall Interpretation
This pharmacogenomic evaluation identified that you are a CYP2C19 intermediate metabolizer due to a *1/*2 genotype. This finding does not represent a disease or abnormal health condition; rather, it provides information about how your body processes certain medications.
The primary importance of this result is to help guide cardiovascular medication decisions, especially those involving drugs affected by CYP2C19 metabolism.
Longitudinal Significance
This report contributes to:
- Cardiovascular History
- Atrial Fibrillation Management
- Medication Response Profile
- Pharmacogenomic Archive
- Physician Consultation Materials
Clinical Importance
⭐⭐⭐⭐ Medication Management Milestone
Although this is not a traditional blood chemistry or inflammatory test, it is a valuable addition to the Health Inventory because it provides lifelong genetic information that may influence future medication decisions.
Key Finding
- CYP2C19 genotype: *1/*2
- Metabolic classification: Intermediate metabolizer
- Primary relevance: Medication processing, especially CYP2C19-dependent cardiovascular medications
Related Reports
- Cardiovascular History
- Atrial Fibrillation Timeline
- Cardiology Consultation Summary
- Medication History
- Physician Provider Directory
- Health Inventory Section 3.3 – History of Atrial Fibrillation
Navigation
- Previous Report: June 7, 2022 – Inflammation Monitoring Evaluation
- Next Report: Subsequent Laboratory Evaluation
- Return to Laboratory Library
- Return to Health Inventory
Observation
This report is different from the previous 20 laboratory reports because it does not measure a current health condition—it documents a lifelong genetic characteristic.
Its value in the Health Inventory is that it adds another layer of personalized medicine. When combined with your cardiovascular history (atrial fibrillation, Watchman implant, prior anticoagulation decisions, and cardiology follow-up), this information gives future physicians additional insight into how medication choices may affect you.
This is exactly the type of information that makes the Health Inventory more than a collection of lab results—it becomes a comprehensive personal medical reference.
Anchor My Faith 